Gilead Tenofovir Cases (Supreme Court of California) March 19, 2024
The case arises from Gilead Sciences’ successful HIV/AIDS drug, tenofovir disoproxil fumarate (TDF). Plaintiffs allege injury from TDF but do not allege any defect with the design, manufacture, marketing, or labeling of TDF. In denying Gilead’s summary judgment motion, the trial court held that Gilead could be held liable in tort for not developing and selling a completely different drug. AdvaMed® noted the decision imposes unfair and unworkable liability upon the life science industry.
Read a copy of the AdvaMed® amicus brief.
Related Reading
News / Amicus Briefs / Compliance / Health Access / Legal
AdvaMed Asks District Court to Recognize Importance of Independent Sales Agent (ISA) Agreements
September 2, 2025
Washington, D.C.—AdvaMed, the Medtech Association, asked the US District Court for the District of Massachusetts to rule as a matter of law that independent sales agent (ISA) arrangements do not — by themselves — violate the Anti-Kickback Statute (AKS) and, accordingly, grant summary judgment in the Langer v Zimmer Biomet case.
Blog / Code of Ethics / Compliance / Legal / Regulatory Affairs / The MedTech Conference
AdvaMed in Action: Legal, Compliance, and Regulatory in the Spotlight at The MedTech Conference 2025
August 27, 2025
Christopher L. White, Esq., AdvaMed’s General Counsel & Chief Policy Officer, on why this year’s legal, compliance & regulatory programming is mission-critical as medtech leaders navigate uncertainty, shifting enforcement priorities, and a rapidly changing global legal landscape.
Resource / Legal
AdvaMed® Medical Device Mass Tort TV Ad Trend – Q2 2025
August 11, 2025
News / Amicus Briefs / Health Access / Legal
AdvaMed Asks U.S. Court of Appeals to Recognize FDA, CMS, and Health Care Provider Decision-Making Concerning Patient Safety
July 23, 2025
Washington, DC.—AdvaMed, the medtech association, asked the Court of Appeals for the Third Circuit to vacate the judgment of the District Court, which if allowed to stand, would have significant and deleterious effects on patient care.
Resource / Compliance / Government & Legislative Affairs / Legal
AdvaMed Comments to HHS Deregulation RFI
July 14, 2025
AdvaMed submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.
Resource / Digital Health / Legal
AdvaMed Response to House Privacy Working Group RFI
May 30, 2025
AdvaMed calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.
Resource / Legal
AdvaMed® Medical Device Mass Tort TV Ad Trend – Q1 2025
May 13, 2025
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Legal
AdvaMed Comments to OMB Deregulation RFI
May 12, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.